Nuvectis launches Phase 1a dose escalation clinical trial of new cancer drug

Clinical trials have begun for a drug candidate for hard-to-treat cancers, discovered at the University of Edinburgh and licensed by US biopharmaceutical company Nuvectis Pharma, Inc.